Cargando…
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to suppress the cytokine signalling cascade caused by...
Autores principales: | Bellido, Mar, te Boekhorst, Peter A. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286888/ https://www.ncbi.nlm.nih.gov/pubmed/22400031 http://dx.doi.org/10.1155/2012/535709 |
Ejemplares similares
-
Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020) -
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019) -
JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice
por: Debeurme, Franck, et al.
Publicado: (2015) -
New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
por: Penna, Domenico
Publicado: (2021) -
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)